SCHEMBL4447696

SCHEMBL4447696

CN1CCN(c2c(O)ccc3c2C=Nc2cc(Cl)ccc2N3)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 6/20 0.52
DRD2 P14416 6/20 0.52
DRD4 P21917 6/20 0.52
HRH4 Q9H3N8 4/20 0.52
DRD3 P35462 3/20 0.52
HRH1 P35367 2/20 0.52
HTR3E A5X5Y0 1/20 0.52
MEN1 O00255 1/20 0.52
CACNA1F O60840 1/20 0.52
HTR3B O95264 1/20 0.52
ABCB11 O95342 1/20 0.52
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
POLB P06746 1/20 0.52
ADRB2 P07550 1/20 0.52
CHRM2 P08172 1/20 0.52
CHRM4 P08173 1/20 0.52
CYP3A4 P08684 1/20 0.52
HTR1A P08908 1/20 0.52
CHRM5 P08912 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3858770 0.84 CHRM1 (0.47) CHRM1DRD2DRD4HRH4DRD3
SCHEMBL3277971 0.81 DRD2 (0.56) CHRM1DRD2DRD4HRH4DRD3
SCHEMBL30416496 0.81 DRD2 (0.56) CHRM1DRD2DRD4HRH4DRD3
Hydrochloric Acid SCHEMBL5445211 0.80 DRD2 (0.55) CHRM1DRD2DRD4HRH4DRD3
SCHEMBL11535134 0.78 DRD2 (0.50) CHRM1DRD2DRD4HRH4DRD3
SCHEMBL5445017 0.75 CHRM1 (0.49) CHRM1DRD2DRD4HRH4DRD3
SCHEMBL142391 0.71 CHRM1 (0.75) CHRM1DRD2DRD4HRH4DRD3
SCHEMBL11533730 0.69 CHRM1 (0.71) CHRM1DRD2DRD4HRH4DRD3
Clozapine SCHEMBL29283918 0.69 DRD2 (0.95) CHRM1DRD2DRD4HRH4DRD3
Clozapine SCHEMBL5501558 0.68 DRD2 (1.00) CHRM1DRD2DRD4HRH4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075951-A1 Methods and Reagents for the Treatment of Inflammatory Disorders COMBINATORX, INC. (US) 2009-03-19 US disclosed
WO-2008085927-A2 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF PAIN COMBINATORX, INCORPORATED (US) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075951-A1 Methods and Reagents for the Treatment of Inflammatory Disorders IL5, TNF, LTC4S CHRM1 3454/4885DRD2 3820/4885DRD4 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.